Kite Pharma
NEWS
BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
The U.S. Food and Drug Administration is wrapping up the end of September and beginning October with two PDUFA dates. Here’s a look.
Gilead won the most recent battle when a U.S. appeals court threw out a $1.2 billion ruling against the company.
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
The new U.S. HQ for Neogene has the backing of biotech guru Arie Belldegrun, CEO of Kite Pharma. The company has leased 38,000 sq. ft. in two Santa Monica buildings.
Appia is developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients.
The U.S. FDA approved Gilead and Kite’s Yescarta (axicabtagene ciloleucel) for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
JOBS
IN THE PRESS